New drug combo aims to extend life in tough colorectal cancer

NCT ID NCT03829462

Ongoing Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether combining regorafenib and irinotecan works better than regorafenib alone for people with metastatic colorectal cancer who have already tried standard treatments. About 377 participants will receive either the combo or the single drug. The main goal is to see if the combo helps people live longer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: regorafenib and irinotecan
What this could lead to: If successful, this combination could offer a new treatment option for patients with metastatic colorectal cancer who have run out of standard therapies.
What could go wrong: This is a late-stage trial, but the cancer is advanced and hard to treat. The combination may not improve survival and could cause more side effects than regorafenib alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (MCRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER (MCRC)

Contacts and locations

Locations

CRLC Val d'Aurelle-Paul Lamarque

Montpellier, 34298, France
Centre Antoine Lacassagne

Nice, Alpes-Maritimes, 06189, France
Centre François Baclesse

Caen, Basse-Normandie, 14000, France
Centre Léon Bérard

Lyon, Rhône, 69008, France
Hôpital Européen Georges Pompidou

Paris, 75015, France
Hôpital Pontchaillou

Rennes, Ile Et Vilaine, 35000, France
Hôpital Robert Debré

Reims, Marne, 51100, France
Hôpital Saint-Jean

Perpignan, Pyrénées-orientales, 66000, France
Hôpital privé Jean Mermoz

Lyon, Rhône, 69008, France
Institut Godinot

Reims, Marne, 51100, France
Institut Gustave Roussy

Villejuif, Val De Marne, 94800, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.